You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
Title |
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
|
---|---|
Published in |
Breast Cancer Research, October 2009
|
DOI | 10.1186/bcr2419 |
Pubmed ID | |
Authors |
Richard S Finn, Judy Dering, Dylan Conklin, Ondrej Kalous, David J Cohen, Amrita J Desai, Charles Ginther, Mohammad Atefi, Isan Chen, Camilla Fowst, Gerret Los, Dennis J Slamon |
Abstract |
Alterations in cell cycle regulators have been implicated in human malignancies including breast cancer. PD 0332991 is an orally active, highly selective inhibitor of the cyclin D kinases (CDK)4 and CDK6 with ability to block retinoblastoma (Rb) phosphorylation in the low nanomolar range. To identify predictors of response, we determined the in vitro sensitivity to PD 0332991 across a panel of molecularly characterized human breast cancer cell lines. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 3 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Scientists | 1 | 33% |
Members of the public | 1 | 33% |
Science communicators (journalists, bloggers, editors) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 804 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 6 | <1% |
Japan | 4 | <1% |
Netherlands | 3 | <1% |
United Kingdom | 2 | <1% |
Spain | 2 | <1% |
Mexico | 2 | <1% |
Brazil | 1 | <1% |
Canada | 1 | <1% |
Egypt | 1 | <1% |
Other | 6 | <1% |
Unknown | 776 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 149 | 19% |
Student > Ph. D. Student | 146 | 18% |
Student > Master | 87 | 11% |
Student > Bachelor | 81 | 10% |
Other | 50 | 6% |
Other | 111 | 14% |
Unknown | 180 | 22% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 176 | 22% |
Medicine and Dentistry | 158 | 20% |
Agricultural and Biological Sciences | 150 | 19% |
Chemistry | 36 | 4% |
Pharmacology, Toxicology and Pharmaceutical Science | 34 | 4% |
Other | 48 | 6% |
Unknown | 202 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 51. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 January 2024.
All research outputs
#836,298
of 26,017,215 outputs
Outputs from Breast Cancer Research
#65
of 2,086 outputs
Outputs of similar age
#2,124
of 111,177 outputs
Outputs of similar age from Breast Cancer Research
#2
of 12 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,086 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.4. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 111,177 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.